Adalimumab Double Take: The Unexpected Return to Reference Humira

June 30, 2025

About 13% of patients who switch from Humira to an adalimumab biosimilar switch back to the originator, according to research from Truveta. However, the presented data may not tell the full story.

Expert Insights on Overcoming Patient Education Gaps, Biosimilar Financial Hurdles

June 29, 2025

The Top 5 Biosimilar Articles for the Week of June 23

June 27, 2025

Eye on Pharma: CHMP Aflibercept Decision; Omalizumab Results; Dupilumab Biosimilar Deal

June 26, 2025

Increasing Biosimilar Use Reflects Changing Practice in Pediatric IBD Care

June 25, 2025

Part 2: Unlocking the Potential of Biosimilars to Improve Health Equity

June 19th 2024

By Cameron Santoro

Article

Part 2 of this series dives into the health care system, revealing financial hurdles that limit biosimilar access and ultimately hinder health equity.

British Columbia’s Biosimilar Switching Program Saves $732 Million in 5 Years

June 18th 2024

By Skylar Jeremias

Article

British Columbia's 2019 Biosimilars Initiative, which transitioned over 40,000 patients from costly reference biologics to biosimilars, saved around $732 million in 5 years, maintained comparable health outcomes, and reinvested the savings to improve the province's public payer program.

BioRationality—How to Promote Science to Secure Waiver of Comparative Efficacy Testing for Biosimilars

June 17th 2024

By Sarfaraz K. Niazi, PhD

Article

Sarfaraz K. Niazi, PhD, makes suggestions for what arguments will help convince the FDA to waive clinical efficacy testing requirements for biosimilar approvals.

Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved

June 16th 2024

By Skylar Jeremias

Podcast

In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.

EHA Poster Shows Transfusion Avoidance Rates Were Comparable Between Eculizumab Biosimilar, Soliris

June 15th 2024

By Skylar Jeremias

Article

A poster from the European Hematology Association’s (EHA) 2024 annual meeting in Madrid, Spain, showed similar rates of transfusion avoidance between patients with paroxysmal nocturnal hemoglobinuria who were administered reference eculizumab (Soliris) and those administered an eculizumab biosimilar (SB12).

The Top 5 Biosimilar Articles for the Week of June 10

June 14th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of June 10, 2024.

Switch to Adalimumab Biosimilar Safe, Effective for Uveitis, but the Nocebo Effect Persists

June 13th 2024

By Cameron Santoro

Article

Switching patients with non-infectious uveitis from originator adalimumab to biosimilar adalimumab-atto was safe and effective, but some patients experienced the nocebo effect, where negative adverse events are caused by patients’ poor perception of the drug rather than the medication itself.

Real-World Study: Nonmedical Switch to Infliximab Biosimilar Is Safe, Effective in Pediatric Patients With IBD

June 12th 2024

By Deana Ferreri, PhD

Article

A real-world study of children and young adults with inflammatory bowel disease (IBD) switched from the infliximab reference product to a biosimilar concluded effectiveness was maintained over 12 months based on stable remission rates and biochemical markers.

New Data Show Safety of Ado-Trastuzumab, Trastuzumab Biosimilars in HER2+ Cancers

June 11th 2024

By Skylar Jeremias

Article

Posters from the American Society of Clinical Oncology annual meeting showcased safety and efficacy data for a trastuzumab biosimilar and an ado-trastuzumab biosimilar in HER2-positive (HER2+) cancers.

Review Finds 7 Themes That Can Help Define the Value of Biosimilars

June 10th 2024

By Skylar Jeremias

Article

Authors of an integrated literature review identified 7 themes that help stakeholders define the value of biosimilar portfolios beyond cost savings, which could provide stakeholders better clarity as to the value of a biosimilar portfolio vs a single biosimilar within a portfolio.